TCIM
NVAX icon

TIAA CREF Investment Management’s Novavax NVAX Stock Holding History

TIAA CREF Investment Management’s Portfolio NVAX Stock Details NVAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		$702K Buy
63,734
+22,622
+55% +$714K ﹤0.01% 2468
2018
Q4 		$1.51M Sell
41,112
-1,372
-3% -$53.2K ﹤0.01% 2113
2018
Q3 		$1.6M Sell
42,484
-2,906
-6% -$81.8K ﹤0.01% 2233
2018
Q2 		$1.22M Buy
45,390
+1,286
+3% +$43.5K ﹤0.01% 2408
2018
Q1 		$1.85M Buy
44,104
+1,654
+4% +$66.4K ﹤0.01% 2150
2017
Q4 		$1.05M Buy
42,450
+215
+0.5% +$5.25K ﹤0.01% 2439
2017
Q3 		$963K Sell
42,235
-2,412
-5% -$54K ﹤0.01% 2534
2017
Q2 		$1.03M Buy
44,647
+1,605
+4% +$31.5K ﹤0.01% 2533
2017
Q1 		$1.1M Sell
43,042
-9,601
-18% -$264K ﹤0.01% 2464
2016
Q4 		$1.33M Buy
52,643
+4,686
+10% +$137K ﹤0.01% 2395
2016
Q3 		$2K Sell
47,957
-4
-0% -$516 ﹤0.01% 2172
2016
Q2 		$6.97M Sell
47,961
-948
-2% -$109K 0.01% 1307
2016
Q1 		$5.05M Sell
48,909
-1,143
-2% -$123K ﹤0.01% 1502
2015
Q4 		$8.4M Sell
50,052
-598
-1% -$92K 0.01% 1182
2015
Q3 		$7.16M Buy
50,650
+4,344
+9% +$974K 0.01% 1275
2015
Q2 		$10.3M Buy
46,306
+6,020
+15% +$1.06M 0.01% 1126
2015
Q1 		$6.66M Sell
40,286
-354
-0.9% -$57.5K ﹤0.01% 1430
2014
Q4 		$4.82M Sell
40,640
-2,081
-5% -$217K ﹤0.01% 1650
2014
Q3 		$3.56M Buy
42,721
+1,721
+4% +$156K ﹤0.01% 1847
2014
Q2 		$3.79M Buy
41,000
+4,296
+12% +$378K ﹤0.01% 1875
2014
Q1 		$3.33M Sell
36,704
-1,055
-3% -$118K ﹤0.01% 1912
2013
Q4 		$3.87M Buy
37,759
+10,873
+40% +$768K ﹤0.01% 1820
2013
Q3 		$1.7M Sell
26,886
-1,218
-4% -$68.6K ﹤0.01% 2314
2013
Q2 		$1.15M Buy
+28,104
New +$1.22M ﹤0.01% 2498

Other funds holding NVAX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

TIAA CREF Investment Management's NVAX Position: Q1 2019 in Review

TIAA CREF Investment Management increased its Novavax (NVAX) stake by 55% in Q1 2019, buying an estimated $714K and bringing the position to 63,734 shares worth $702K. The position accounts for ﹤0.01% of the portfolio, ranked #2468.

TIAA CREF Investment Management first reported a position in NVAX in Q2 2013 and has held it in 24 quarters since. The position peaked at $10.3M in Q2 2015. 140 funds tracked by Wall St. Rank hold NVAX as of Q1 2019.

  • TIAA CREF Investment Management held 63,734 shares of Novavax worth $702K as of Q1 2019.
  • TIAA CREF Investment Management bought 22,622 Novavax shares in Q1 2019, an estimated $714K.
  • Novavax made up ﹤0.01% of TIAA CREF Investment Management's portfolio in Q1 2019, its #2468 holding.
  • TIAA CREF Investment Management first reported a position in Novavax in Q2 2013 and has held it in 24 quarters since.
  • TIAA CREF Investment Management's Novavax position peaked at $10.3M in Q2 2015.
  • 140 funds tracked by Wall St. Rank held Novavax as of Q1 2019.

Based on TIAA CREF Investment Management's 13F filing for Q1 2019, filed 14 May 2019.